fbpx

molecules of the month

compound 14

potent HIV-1 protease inhibitor

in vitro activity (IC50 = 0.0071 μM, EC50 = 0.86 μM)

from “pocket-to-lead” virtual screen and SBDD

J. Med. Chem.

Shionogi, Osaka, JP

compound 14 chemical structure, potent HIV-1 protease inhibitor - Shionogi, Osaka, JP
2 mins read

Context.  “Compound 14” (Shionogi) is an HIV-1 protease inhibitor being developed for HIV treatment. Despite the existence of two generations and a total of nine approved agents targeting the well-validated HIV-1 protease, issues with drug resistance and toxicity still persist, highlighting the need for novel agents with unique mechanisms of action. Shionogi scientists adopted a novel “Pocket-to-Lead” strategy utilizing HIV-1 as the target to identify and optimize “compound 14” which exhibited promising in vitro efficacy and could provide a useful tool to further develop novel inhibitors targeting the protein. Hit-Finding Strategy.  A novel strategy named “Pocket-to-Lead” employed docking and de novo design. This strategy was applied to the Shionogi Virtual Library (SVL). As a result of the virtual screening, a…


request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.


already a member? log in: